Prolong Management “the Team”
Prolong’s senior management team includes inventors of the most successful drug delivery technology in pharmaceutical history, PEGylation, now responsible for the development of many drugs improving the quality of life for sufferers of hepatitis, kidney disease, and a number of life-threatening diseases.
Our leadership has led and been associated with a number of successful pharmaceutical and biotechnology companies. With proven credentials, and highly regarded scientific backgrounds, we bring our passion and commitment to developing important new drugs. Click the photograph of the team member for an expanded biography.
Sandeep Gupta, PhD
Chief Executive Officer
Prolong Pharmaceuticals is led by Dr. Sandeep Gupta, who was previously the Senior Vice-President of Discovery and Early Development, Endo Pharmaceuticals. Prior to Endo, Dr. Gupta spent a decade at Forest Laboratories as Head of Drug Discovery and Pharmacology. He played a key role in the development of several block buster drugs during his tenure at Endo and Forest. Before Forest Laboratories, Dr. Gupta held academic positions at the University of Pennsylvania and Boston University Schools of Medicine. Regarded as an architect of the Virtual Drug Discovery Research model, he has pioneered several successful Discovery and Development collaborations across the globe. He is a co-inventor on multiple patents and has authored over 50 scientific papers, presentations and book chapters.
Louis Denis, MD
Chief Medical Officer
Louis Denis, MD is a medical oncologist with more than 20 years of academic and industry experience in oncology and clinical cancer drug development, including first-in-human and global registration trials. Dr. Denis held strategic and leadership positions of increasing responsibility in Clinical Development and Medical Affairs at Pfizer and Boehringer-Ingelheim. Dr. Denis earned an MD degree from the Vrije Universiteit Brussels, Belgium, and did his post-doctoral fellowships in Internal Medicine/Medical Oncology at Middelheim Hospital, Antwerp; the Rotterdam Cancer Institute, The Netherlands; and the Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas. He is co-inventor on multiple patents and is co-author of over 30 scientific publications and presentations on cancer clinical research.
Head of Operations and Quality
Shashank Mahashabde has over 30 years of experience in the pharmaceutical industry in Research and Development at Schering Plough Research Institute and Forest Research Institute. He has extensive experience in development of all dosage forms and has been involved in several NDAs and development of 19 products on the market. Most recently, he was President of Business Development and Marketing for North America at Neuland Laboratories Inc. He has several applied and issued patents.
Niranjan Rao, PhD FCP
Head of Clinical Operations
Dr. Rao has 30 years of drug development experience in a variety of therapeutic areas at Aventis, Forest Laboratories, Kyowa Hakko Kirin Pharma and Endo Pharmaceuticals. He has held positions of increasing scope and responsibility over the course of his career. He has led early clinical development programs in oncology and has been an important contributor on several NDAs and approved drugs. He is a co-inventor on multiple patents and has published or presented over 60 scientific papers.
Pablo Jimenez, MD, FAPRC
Vice President – Therapeutic Area Head Immunology
Dr. Jimenez is a Senior pharmaceutical executive physician with more than 20 years of experience in clinical research, regulatory, and medical affairs in the dermatology, rheumatology, and respiratory therapeutic areas. His product business development expertise includes atopic dermatitis, psoriasis, asthma and wound healing. Dr. Jimenez earned an MD degree from the Central University, Ecuador, and did his post-doctoral work at Brown University. He is a fellow of the Academy of Physicians in Clinical Research (FAPCR). He holds a successful track record in executive leadership positions at premier biopharmaceutical and pharmaceutical companies, such as Human Genome Sciences, Novartis, Celsus, and Ziarco. He is co-inventor on multiple patents and is co-author of numerous scientific publications and presentations.
Vice President – Early Development
Dr. Jubin is Vice President of Research and Development at Prolong Pharmaceuticals and brings more than two decades of experience at the forefront of drug discovery. Ron’s experience includes key roles at Schering-Plough Research Institute and PBL Biomedical labs. At Schering-Plough, Dr. Jubin served in major roles in the hepatitis C protease program, directed other HCV inhibitor programs, and managed internal committees evaluating licensing opportunities for a novel interferon candidate. At PBL Biomedical, his tenure leading the Research and Development department at PBL resulted in the development of numerous interferon proteins, reagents, and functional assay for evaluating immune and interferon functions. Dr. Jubin received his PhD in Microbiology and Molecular Genetics from the UMDNJ-NJMS Graduate School of Biomedical Sciences, Newark, NJ.
Tara Chapman, PharmD
Head of Regulatory Affairs
Dr. Chapman has 20 years of experience in the pharmaceutical industry in various therapeutic areas, including respiratory, inflammation, pain, oncology and dermatology. Her strategic regulatory experience ranges from pre-IND through post-marketing activities, including leading or contributing to various IND, NDA, and sNDA filings, Advisory Committee meetings, shared post-marketing requirements and shared REMS programs. Dr. Chapman was most recently Senior Director, Regulatory Affairs at Endo Pharmaceuticals, and previously held positions of increasing responsibility at AstraZeneca and Wyeth (now Pfizer).